#biopharmaceutical - Techseriesinsight

May 1, 2025
PRNewswire
Biotechnology

Dynavax Announces Nationwide Harris Poll Survey Results Finding Americans Underestimate the Serious Consequences of Hepatitis B and Vaccine Protection Benefits

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, today announced the results of the Hepatitis B Perceptions and Insights Survey conducted by The Harris Poll, which...

April 29, 2025
PRNewswire
Biotechnology

Lutris Pharma Announces the Appointment of Seasoned Life Science Executive, Sumant Ramachandra, M.D., Ph.D., as Chief Executive Officer

Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous dose limiting toxicity, today announced that, effective April 20, 2025, the Board of Directors has appointed Sumant Ramachandra, M.D., Ph.D. as Chief...

April 22, 2025
PRNewswire
Healthcare

Angel MedFlight Earns Fourth Consecutive NAAMTA Global Accreditation

NAAMTA Global and Angel MedFlight are pleased to announce the renewal of Angel MedFlight’s accreditation for a fourth consecutive three-year term. This reaccreditation reflects Angel MedFlight’s consistent adherence to the highest standards...

April 17, 2025
PRNewswire
Healthcare

Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced positive appetite suppression results...

April 17, 2025
PRNewswire
Healthcare

Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that a new...

April 17, 2025
PRNewswire
Biotechnology

Dynavax Files Definitive Proxy Statement and Sends Letter to Stockholders

Dynavax Technologies Corporation (Nasdaq: DVAX) (“Dynavax” or the “Company”), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that it has filed definitive proxy materials with the Securities and Exchange...

April 14, 2025
PRNewswire
Biotechnology

Palatin Appeals NYSE American Notice of Delisting

Palatin Technologies, Inc. (the “Company”) (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced today that...

April 14, 2025
PRNewswire
Biotechnology

Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today...

March 24, 2025
PRNewswire
Biotechnology

Tempero Bio Secures $70 Million Series B Financing to Advance TMP-301 into Phase 2 Trials for Substance Use Disorders

Tempero Bio, Inc., a clinical-stage biopharmaceutical company developing transformative treatments for substance use disorders, today announced the closing of a $70 million Series B financing. The financing was led by 8VC...

March 21, 2025
PRNewswire
Healthcare

Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets

Pulmatrix, Inc. (“Pulmatrix” or the “Company”) (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases...